BioSig Introduces New Subscription Model for PURE EP Platform, Offering Quicker Access to Latest Features, Customizations

Cleveland Clinic, the #1 heart center in the Nation, signs on as first subscriber to receive latest software advancements in intracardiac signal visualization

Westport, CT, Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today a subscription model for its PURE EP Platform. Cleveland Clinic—recently ranked as number one in the Nation for cardiology, heart & vascular surgery by U.S. News & World Report¹—is first to sign an agreement to acquire the PURE EP Platform under the subscription model.

BioSig has made the move to a subscription model so that electrophysiologists and cardiology departments can access the latest features with the ability to customize the rich suite of PURE EP software capabilities to suit their needs. The proprietary combination of hardware and software empowers electrophysiologists with real-time, ultra-pure, cardiac signal data, with the potential to improve arrhythmia care and procedures. 

“At BioSig, we aspire to be a true partner to the electrophysiology community; constantly advancing our technology to push the boundaries of signal hygiene, analysis, and data application," said Gray Fleming, Chief Commercial Officer of BioSig. “This subscription model expands access to PURE EP’s novel and configurable software features as they become available and supports operational expenditure goals by optimizing case-by-case and day-to-day department expenses, removing the burden of ownership and maintenance.”

The agreement follows BioSig’s exhibition at the Heart Rhythm Society 2023 (“HRS 2023”) in May, known for being the largest gathering of heart rhythm professionals worldwide. During the conference, research conceptualized and spearheaded by Cleveland Clinic’s world-class physician faculty highlighted the PURE EP Platform’s ability to optimize ablation procedures. The data compared the efficacy of PURE EP’s unipolar signal guidance to the current standard, the Ablation Index for radiofrequency ablation procedures during pulmonary vein isolation. Topline findings from the physician-initiated research revealed a 66% reduction in procedure time while maintaining accuracy, and enhancing precision during PVI.^2,3,4